#United States #Genomics #Helix #Boston, Massachusetts #ASHG2025

Helix to Showcase Innovative Genomic Research at ASHG 2025

Helix, a prominent player in the field of enterprise genomics, is gearing up to present its latest clinical research at the American Society of Human Genetics (ASHG) 2025 Annual Meeting. This prestigious event will take place from October 14 to 18, 2025, in Boston, Massachusetts. Helix's presentations will delve into cutting-edge findings emphasizing the role of genomic data in enhancing clinical care.

Helix's research highlights the advancements made possible through the Helix Research Network® (HRN), which stands as North America’s most extensive precision health network. This network boasts a diverse dataset encompassing over 1.5 million patients, 500,000 sequenced exomes, and more than 12 years of longitudinal electronic health record data. These resources dramatically accelerate genomic discoveries, translating insights into impactful clinical applications while empowering healthcare systems to adopt precision medicine strategies.

Key Research Areas

The focus of Helix's presentations spans various therapeutic domains, shedding light on pressing health issues such as cardiovascular disorders, autoimmune diseases, and mental health concerns. William Lee, Ph.D., Chief Science Officer at Helix, articulated the significance of genomics in modern healthcare, stating, "The expansion of genomic insights into clinical practice enables earlier interventions and more effective therapies tailored to individual patients. Our findings will demonstrate how population-scale genomics shapes tangible changes in real-world clinical settings to improve patient outcomes."

Here’s a snapshot of some key presentations scheduled during the event:

• - Hypercholesterolemia Polygenic Score: Discussing the modulating effects of polygenic scores on statin therapy responses, presented by Dr. Liz Cirulli on October 16.
• - Resolving Variants of Uncertain Significance (VUS): Examining statistical correlations from clinico-genomic datasets, presented by Dr. Matt Ferber on October 15.
• - Lynch Syndrome: Investigating the clinical utility of genomic screening for PMS2 pathogenic variants, also presented on the 15th by Dr. Kate Lynch.
• - Patient Behavioral Impact: Analyzing how genomic screening influences preventive screening behaviors among individuals positive for HBOC, presented by Dr. Cassie Hajek on October 15.
• - Pharmacogenomic Alleles: Exploring the outcome disparities in mental health treatment linked to pharmacogenomic alleles, with insights by Dr. Natalie Telis, also on the 15th.

Further presentations will delve into rare variant analyses, the clinical ramifications of inborn errors of immunity in adults, and the impact of population genomic screening on managing familial hypercholesterolemia.

Join Helix at ASHG 2025

Attendees of the ASHG 2025 Annual Meeting are invited to visit Helix at booth #2074 to discover more about their groundbreaking genomic research and its implications for future healthcare innovations.

About Helix

Helix stands at the forefront of genomic data integration, enabling health systems, life sciences entities, and payers to accelerate the use of genomic information in patient care and therapeutic developments. To explore more about Helix and its initiatives, visit www.helix.com.

For media inquiries, please contact:
[Email Address]